Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Hongying Zhang

Fei Liu

Yizhong Zhu

Xiquan Zhang

Ling Yang

Hongjiang Xu

Shanchun Wang

Wei Shi

Hongmei Gu

Yanlong Liu

Song Tang

Lulu Wang

Weiwei Feng

Xujing Tang

Bin Wang

Jinan Wang

Jianqing Zhang

Yiyan Yao

Yang Li

Limin Liu

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a compound of formula V as a raw material. 

Method for preparing intermediate of 6-arylaminopyridonecarboxamide compound as MEK inhibitor

Growing community of inventors

Jiangsu, China

Hongying Zhang